Last edition
News about "Dr. Helen Torley"
Merus, Halozyme Partner to Develop Subcutaneous Petosemtamab
Under the agreement, Merus will pay Halozyme upfront and milestone-based payments, with Halozyme also eligible for low- to mid-single-digit royalties on future ENHANZE-enabled petosemtamab sales.
Dr Helen Torley | 19/11/2025 | By Dineshwori
FDA Approves DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma
The US FDA has approved DARZALEX Faspro as the first treatment for adult patients with High-Risk Smoldering Multiple Myeloma (HR-SMM), marking a key milestone in addressing this early stage of the disease.
Dr Helen Torley | 11/11/2025 | By Dineshwori
European Commission Approves DARZALEX Faspro for Adults with Smouldering Multiple Myeloma
Halozyme Therapeutics has announced European Commission approval for DARZALEX Faspro, co-formulated with ENHANZE, as a monotherapy for high-risk smouldering multiple myeloma in adults, marking a shift from passive monitoring to early intervention.
Dr. Helen Torley | 24/07/2025 | By Mrinmoy Dey | 133
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy